1. Market Research
  2. > Nosocomial Infections – Pipeline Review, H1 2013

Nosocomial Infections – Pipeline Review, H1 2013

  • March 2013
  • -
  • Global Markets Direct
  • -
  • 87 pages

Nosocomial Infections – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Nosocomial Infections - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Nosocomial Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Nosocomial Infections. Nosocomial Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Nosocomial Infections.
- A review of the Nosocomial Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Nosocomial Infections pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Nosocomial Infections.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Nosocomial Infections pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Nosocomial Infections - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Nosocomial Infections Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Nosocomial Infections 9
Nosocomial Infections Therapeutics under Development by Companies 11
Nosocomial Infections Therapeutics under Investigation by Universities/Institutes 13
Late Stage Products 14
Comparative Analysis 14
Mid Clinical Stage Products 15
Comparative Analysis 15
Early Clinical Stage Products 16
Comparative Analysis 16
Discovery and Pre-Clinical Stage Products 17
Comparative Analysis 17
Nosocomial Infections Therapeutics - Products under Development by Companies 18
Nosocomial Infections Therapeutics - Products under Investigation by Universities/Institutes 19
Companies Involved in Nosocomial Infections Therapeutics Development 20
AstraZeneca PLC 20
Merck and Co., Inc. 21
Rib-X Pharmaceuticals, Inc. 22
Cubist Pharmaceuticals, Inc. 23
Paratek Pharmaceuticals, Inc. 24
Achaogen Inc. 25
Priaxon AG 26
Atox Bio Inc. 27
Integrated BioTherapeutics, Inc. 28
Ancora Pharmaceuticals Inc. 29
Tetraphase Pharmaceuticals Inc. 30
AIMM Therapeutics B.V. 31
Cantab Biopharmaceuticals Limited 32
Da Volterra 33
Nosocomial Infections - Therapeutics Assessment 34
Assessment by Monotherapy Products 34
Assessment by Combination Products 35
Assessment by Route of Administration 36
Assessment by Molecule Type 38
Drug Profiles 40
omadacycline tosylate - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
delafloxacin - Drug Profile 43
Product Description 43
Mechanism of Action 43
RandD Progress 43
NVB-333 - Drug Profile 46
Product Description 46
Mechanism of Action 46
RandD Progress 46
(ceftolozane + tazobactam) - Drug Profile 47
Product Description 47
Mechanism of Action 47
RandD Progress 47
MAR Program - Drug Profile 49
Product Description 49
Mechanism of Action 49
RandD Progress 49
eravacycline - Drug Profile 50
Product Description 50
Mechanism of Action 50
RandD Progress 50
(avibactam + ceftazidime) - Drug Profile 52
Product Description 52
Mechanism of Action 52
RandD Progress 52
Antiinfectives PXO Program - Drug Profile 54
Product Description 54
Mechanism of Action 54
RandD Progress 54
Multivalent Staph Vaccine - Drug Profile 55
Product Description 55
Mechanism of Action 55
RandD Progress 55
CXA-201 + [metronidazole] + [meropenem] - Drug Profile 56
Product Description 56
Mechanism of Action 56
RandD Progress 56
ACHN-978 - Drug Profile 57
Product Description 57
Mechanism of Action 57
RandD Progress 57
MK-7655 - Drug Profile 58
Product Description 58
Mechanism of Action 58
RandD Progress 58
Vaccine For Staphylococcus - Drug Profile 60
Product Description 60
Mechanism of Action 60
RandD Progress 60
Vaccine For Pseudomonas - Drug Profile 61
Product Description 61
Mechanism of Action 61
RandD Progress 61
Vaccine For Enterococcus - Drug Profile 62
Product Description 62
Mechanism of Action 62
RandD Progress 62
Clostridium Dificile Program - Drug Profile 63
Product Description 63
Mechanism of Action 63
RandD Progress 63
IMX313-Ag - Drug Profile 64
Product Description 64
Mechanism of Action 64
RandD Progress 64
DAV-148 - Drug Profile 65
Product Description 65
Mechanism of Action 65
RandD Progress 65
Enoyl Reductase Inhibitors - Drug Profile 66
Product Description 66
Mechanism of Action 66
RandD Progress 66
Nosocomial Infections Therapeutics - Drug Profile Updates 67
Nosocomial Infections Therapeutics - Discontinued Products 75
Nosocomial Infections Therapeutics - Dormant Products 76
Nosocomial Infections - Product Development Milestones 77
Featured News and Press Releases 77
Sep 12, 2012: Tetraphase Pharma Announces Positive Phase II Data For Eravacycline In Patients With Complicated Intra-Abdominal Infections 77
Sep 07, 2012: Kalidex Pharma To Present Clinical Data On Next-generation Fluoroquinolone KPI-10 At ICAAC 2012 78
Sep 05, 2012: Tetraphase Pharma To Present New Clinical And Preclinical Research On Antibiotic Portfolio At ICAAC 2012 79
May 07, 2012: Integrated BioTherapeutics Receives $600,000 Phase I SBIR Grant For Novel Staph Vaccine 79
Dec 13, 2011: Cubist Announces First Patient Dosed In Pivotal Global Phase III Trial Of CXA-201 For Complicated Intra-Abdominal Infections 80
Oct 14, 2011: Nationwide Children's Hospital Clinical Trial To Use Drug To Boost Immune System Function In Critically Injured Children, May Prevent Infection 80
Oct 25, 2010: Intercell Announces Positive Results From Phase II Pseudomonas Aeruginosa Investigational Vaccine Study For Certain Hospital-Acquired Infections 81
Mar 18, 2010: Achillion Announces Award Of NIH Grant To Study Unique Antibacterial Compound Series 82
Jan 28, 2010: Theravance Receives Response Letter From FDA For Telavancin NDA For The Treatment Of Nosocomial Pneumonia 83
Dec 14, 2009: Cubist Pharmaceuticals To Acquire Calixa Therapeutics 84
Appendix 86
Methodology 86
Coverage 86
Secondary Research 86
Primary Research 86
Expert Panel Validation 86
Contact Us 87
Disclaimer 87



List of Tables

Number of Products Under Development for Nosocomial Infections, H1 2013 9
Products under Development for Nosocomial Infections - Comparative Analysis, H1 2013 10
Number of Products under Development by Companies, H1 2013 12
Number of Products under Investigation by Universities/Institutes, H1 2013 13
Comparative Analysis by Late Stage Development, H1 2013 14
Comparative Analysis by Mid Clinical Stage Development, H1 2013 15
Comparative Analysis by Early Clinical Stage Development, H1 2013 16
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 17
Products under Development by Companies, H1 2013 18
Products under Investigation by Universities/Institutes, H1 2013 19
AstraZeneca PLC, H1 2013 20
Merck and Co., Inc., H1 2013 21
Rib-X Pharmaceuticals, Inc., H1 2013 22
Cubist Pharmaceuticals, Inc., H1 2013 23
Paratek Pharmaceuticals, Inc., H1 2013 24
Achaogen Inc., H1 2013 25
Priaxon AG, H1 2013 26
Atox Bio Inc., H1 2013 27
Integrated BioTherapeutics, Inc., H1 2013 28
Ancora Pharmaceuticals Inc., H1 2013 29
Tetraphase Pharmaceuticals Inc., H1 2013 30
AIMM Therapeutics B.V., H1 2013 31
Cantab Biopharmaceuticals Limited, H1 2013 32
Da Volterra, H1 2013 33
Assessment by Monotherapy Products, H1 2013 34
Assessment by Combination Products, H1 2013 35
Assessment by Stage and Route of Administration, H1 2013 37
Assessment by Stage and Molecule Type, H1 2013 39
Nosocomial Infections Therapeutics - Drug Profile Updates 67
Nosocomial Infections Therapeutics - Discontinued Products 75
Nosocomial Infections Therapeutics - Dormant Products 76



List of Figures

Number of Products under Development for Nosocomial Infections, H1 2013 9
Products under Development for Nosocomial Infections - Comparative Analysis, H1 2013 10
Products under Development by Companies, H1 2013 11
Products under Investigation by Universities/Institutes, H1 2013 13
Late Stage Products, H1 2013 14
Mid Clinical Stage Products, H1 2013 15
Early Clinical Stage Products, H1 2013 16
Discovery and Pre-Clinical Stage Products, H1 2013 17
Assessment by Monotherapy Products, H1 2013 34
Assessment by Combination Products, H1 2013 35
Assessment by Route of Administration, H1 2013 36
Assessment by Stage and Route of Administration, H1 2013 37
Assessment by Molecule Type, H1 2013 38
Assessment by Stage and Molecule Type, H1 2013 39

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.